Clinical Trials Logo

Filter by:
NCT ID: NCT04109755 Recruiting - Rectal Cancer Clinical Trials

Neo-adjuvant Pembrolizumab and Radiotherapy in Localised MSS Rectal Cancer

PEMREC
Start date: June 2, 2020
Phase: Phase 2
Study type: Interventional

This project investigates the clinical and biological impact of combining immunotherapy (pembrolizumab) with short course radiotherapy (5Gy, five times) in the neo-adjuvant treatment of localised microsatellite stable (MSS) rectal cancer.

NCT ID: NCT04109066 Completed - Breast Cancer Clinical Trials

Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer

CheckMate 7FL
Start date: November 20, 2019
Phase: Phase 3
Study type: Interventional

A randomized multi-arm study evaluating the efficacy and safety of nivolumab versus placebo in combination with neoadjuvant (pre-surgery) chemotherapy and adjuvant (post-surgery) endocrine therapy in participants with high-risk, estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+, HER2-) early stage breast cancer.

NCT ID: NCT04108884 Completed - Atrial Fibrillation Clinical Trials

RedStroke - Reducing Europe's Stroke Incidence

RedStroke
Start date: October 22, 2019
Phase: N/A
Study type: Interventional

In the RedStroke study, the effect of a smartphone application in detecting Atrial Fibrillation (AF) will be assessed in a double-blind randomised controlled multicenter trial. Outpatients with an elevated risk for atrial fibrillation will be randomized to an intervention arm (app group) and to a standard-of-care arm (control group). Both groups will have the app installed on their private smartphones and will be asked to perform a predefined measurement protocol. All patients will continue their prior therapy with their general practitioner and obtain every medical treatment indicated. This study will not cause any restrictions on the usual treatment of the study patients. The only difference between the two groups will be, that patients in the app group will be informed by their local PI, if the recordings of the app indicate AF (and obtain a 14 day Holter ECG for AF verification), whereas the patients in the "usual care" group will obtain the read out of the app at the end of the study.

NCT ID: NCT04108741 Recruiting - Parkinson Disease Clinical Trials

Augmented Reality Treadmill Training in Patients With Parkinson's Disease

Falls_in_PD
Start date: September 15, 2020
Phase: N/A
Study type: Interventional

Gait disorder is a disabling symptom in Parkinson's disease (PD) affecting all patients during the course. Three methods of treadmill training (TT) will be compared to assess additional augmented reality (AR), or additional dual task (DT). AR TT, DT TT, and TT alone applied over 3 weeks at each day will be compared for their impact on falls, walking, freezing and attention for 3 months in a double blinded randomized controlled trial during regular neurorehabilitation.

NCT ID: NCT04108416 Completed - Clinical trials for Cleft Lip and Palate

Unilateral Cleft Repair in One Surgery With Pure Primary Healing

Start date: January 1, 2014
Phase:
Study type: Observational

Retrospective analysis of the current surgical method to repair unilateral cleft lip and palate malformations at our centre

NCT ID: NCT04107454 Active, not recruiting - Clinical trials for Lichen Sclerosus Et Atrophicus of the Vulva

Effect of Treatment With the Ablative Fractional Carbodioxide Laser in Vulvar Lichen Sclerosis

Start date: January 1, 2020
Phase: N/A
Study type: Interventional

Aim of this study is to evaluate the therapeutic effect of the laser treatment in vulvar LS, mainly the reduction of existing symptoms. As measured by visual analogue scale (VAS) symptoms as itching, burning, pain will be determined six weeks after the last laser treatment. Secondary endpoints will be sexual function measured with the female sexual function index (FSFI) and the vulvar skin changes measured by the Lichen score (LS). Regular photo-documentation of the treated skin will demonstrate a potential change of the tissue.

NCT ID: NCT04106583 Active, not recruiting - Aneurysm, Brain Clinical Trials

Assessing the WAVE Extra Soft Coil in Intracranial Aneurysms and Comparing Imaging Modalities

SURF
Start date: November 5, 2019
Phase:
Study type: Observational

The objective of this study is to demonstrate the safety and efficacy of the Penumbra SMART COIL® System, including the WAVE™ Extra Soft Coils (WAVE) as a fill and finish coil, in the treatment of intracranial aneurysms. Imaging will be analyzed by an independent core lab to assess aneurysm occlusion rates and perform a comparative analysis between imaging modalities.

NCT ID: NCT04106427 Completed - Schizophrenia Clinical Trials

Brain Stimulation And Group Therapy to Improve Gesture and Social Skills in Psychosis (BrAGG-SoS)

BrAGG-SoS
Start date: December 1, 2019
Phase: N/A
Study type: Interventional

Randomized, double-blind, placebo-controlled clinical trial testing the effects of 10 sessions of continuous theta burst stimulation and the effects of 16 sessions of social cognitive remediation therapy on gesture performance and nonverbal communication skills in schizophrenia

NCT ID: NCT04105660 Completed - Anesthesia Clinical Trials

Electroencephalogram (EEG) in General Anaesthesia - More Than Only a Bispectral Index (BIS)

Start date: July 1, 2021
Phase: N/A
Study type: Interventional

Processed electroencephalogram (EEG) monitors are routinely used in addition to clinical parameters to assess the depth of anaesthesia during general anaesthesia.

NCT ID: NCT04104828 Completed - Allergic Rhinitis Clinical Trials

Comparison of Innate Immune Responses Induced by Allergy Immunotherapy (AIT) With Different Adjuvants

Start date: November 5, 2019
Phase:
Study type: Observational

The primary objective of the pilot study is to compare inflammatory responses in blood sera from patients receiving first allergen immunotherapy (AIT) with aluminium (Alum), microcrystalline tyrosine (MCT), or a combination of MCT and monophosphoryl lipid A (MPLA) as adjuvants. The AIT products are containing allergen extracts of grass and tree pollen). Blood is collected before as wells as one day, seven days, and 6-7 weeks after first AIT, and the blood is analysed for content of inflammatory proteins and antibodies.